Business Context and Reporting Period
This Form 8-K Current Report was filed by Transdel Pharmaceuticals, Inc. on May 13, 2011. The filing addresses significant changes in the company's executive leadership and board composition.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
- Resignation: John N. Bonfiglio, Ph.D., resigned as Chief Executive Officer and as a director on the Board, effective May 13, 2011.
- Appointment: John T. Lomoro, the company's current Chief Financial Officer, was appointed as the new principal executive officer on the same date.
- Reason for Departure: The resignation was not in connection with any known disagreement with the Company on any matter.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future operations. No specific risks, contingencies, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the effective date of the leadership transition (May 13, 2011).
- Confirm the new title and responsibilities of John T. Lomoro as principal executive officer.
- Review subsequent filings for any interim CEO appointment or board composition updates.